Prevalence and role of low skeletal muscle mass (LSMM) in hepatocellular carcinoma. A systematic review and meta-analysis

March, Christine; Omari, Jazan; Thormann, Maximilian; Pech, Maciej; Wienke, Andreas; Surov, Alexey

doi:10.1016/j.clnesp.2022.04.009

Cited by 21 publications

(22 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sarcopenia was reported as an important risk factor for HCC and a prognostic factor for patients with HCC. 102 In accordance with the results of a meta-analysis, sarcopenia was frequently identified in patients with T2DM (18%). 103 Older age and chronic hyperglycemia were significant risk factors for sarcopenia, whereas gender and BMI were controversial as risk factors for sarcopenia.…”

Section: Metformin Inhibits Development Of Hccsupporting

confidence: 80%

See 1 more Smart Citation

Influence of diabetes mellitus and effectiveness of metformin on hepatocellular carcinoma

Ono

Fujita

Kobayashi

et al. 2023

Hepatology Research

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common cancers, and it is important to elucidate the carcinogenic factors and improve the recurrence and prognosis of HCC patients. Diabetes mellitus (DM) has been reported to be a risk factor for the carcinogenesis of many cancers including HCC, and the mechanism of DM for carcinogenesis is gradually being elucidated. Metformin, a drug for DM, has been reported to have anticancer effects on many cancers, including HCC. Metformin not only suppresses carcinogenesis but also improves the prognosis of recurrence after treatment, and there are many reports on the mechanism of these effects. In this review, we describe the mechanism of action of hyperglycemia and hyperinsulinemia on carcinogenesis by DM against HCC. The carcinogenic effects of DM on hepatitis B, hepatitis C, and nonalcoholic fatty liver disease by etiology are also described. In addition, the carcinogenic effect of metformin on HCC and its mechanism of action are reviewed. We also discuss the effects of metformin on recurrence after hepatectomy and radiofrequency therapy and the effects of metformin in combination with anticancer medicine, focusing on the inhibition of HCC development.

show abstract

Section: Metformin Inhibits Development Of Hccsupporting

confidence: 80%

“…Sarcopenia was reported as an important risk factor for HCC and a prognostic factor for patients with HCC 102 . In accordance with the results of a meta‐analysis, sarcopenia was frequently identified in patients with T2DM (18%) 103 .…”

Section: Introductionsupporting

confidence: 80%

Influence of diabetes mellitus and effectiveness of metformin on hepatocellular carcinoma

Ono

Fujita

Kobayashi

et al. 2023

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…These data on the prevalence of sarcopenia in patients with COVID-19 can also be examined in comparison with that of LSMM prevalence in critically ill patients and patients with COVID-19. Because of its accuracy in body composition measurement and availability in the clinical setting, LSMM is frequently measured through computed tomography scan (CT scan) in clinical practice and is a surrogate parameter for sarcopenia ( 63 , 64 ). It is observed in a published systematic review and meta-analysis that CT-defined LSMM is highly prevalent in critically ill patients with different underlying diagnoses and the pooled prevalence of LSMM was 50.9% ( 65 ).…”

Section: Discussionmentioning

confidence: 99%

Prevalence of Sarcopenia in Patients With COVID-19: A Systematic Review and Meta-Analysis

Xu²,

Peng³

et al. 2022

Front. Nutr.

View full text Add to dashboard Cite

BackgroundIt has been speculated that patients with sarcopenia are aggravated by the current novel coronavirus disease 2019 (COVID-19) epidemic. However, there is substantial uncertainty regarding the prevalence of sarcopenia in patients with COVID-19.ObjectivesThe purpose of the study was to systematically evaluate the prevalence of sarcopenia in patients with COVID-19, including stratification by gender, study location, study population, study design, and diagnostic criteria.DesignThis is the systematic literature review and meta-analysis.MethodsAn electronic search was performed in MEDLINE/PubMed, Embase, Cochrane Library, and Web of Science and Scopus to identify observational studies reporting a prevalence estimate for sarcopenia in patients with COVID-19. Studies were reviewed in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and a meta-analysis was performed. Risk of bias (RoB) was assessed using the Newcastle–Ottawa Scale (NOS) for cohort studies and Joanna Briggs Institute (JBI) manual for cross-sectional studies, and Stata 14.0 was used to perform meta-analyses.ResultsA total of 4,639 studies were initially identified. After removing the duplicates and applying the selection criteria, we reviewed 151 full-text studies. A total of 21 studies, including 5,407 patients, were eligible for inclusion in this review finally. The prevalence of sarcopenia in patients with COVID-19 in individual studies varied from 0.8 to 90.2%. The pooled prevalence of sarcopenia in COVID-19 was 48.0% (95% confidence interval, CI: 30.8 to 65.1%, I2 = 99.68%, p = 0.000). We did not find any significant differences in the prevalence estimates between gender specificity (OR = 1.34; 95% CI = 0.80–2.26; p = 0.001). By sex, the prevalence was 42.5% (95% CI: 31.7 to 53.4%) in men and 35.7% (95% CI: 24.2 to 47.2%) in women. The prevalence estimates significantly varied based on population settings and different diagnostic criteria of sarcopenia. ICU patients (69.7, 95% CI: 51.7 to 85.2%) were more likely to suffer from sarcopenia compared to other population settings.ConclusionTo our knowledge, this is the first meta-analysis reporting on the prevalence of sarcopenia in patients with COVID-19. Sarcopenia is frequently observed in patients with COVID-19, with varying prevalence across population settings. This study would be useful for clinicians to prompt the increasing awareness of identifying sarcopenia and developing interventions at patients with COVID-19 with high risk of sarcopenia. Further prospective longitudinal studies to define the association of sarcopenia and its prognostic outcomes in COVID-19 survivors are urgently needed to propose the most appropriate treatment strategies during their admission and discharge.Systematic Review Registration[www.crd.york.ac.uk/prospero/], identifier [CRD42022300431].

show abstract

“…21 Interestingly, LSMM was also associated with lower recurrence-free survival after tumour resection (HR = 1.79, 95% CI: 1.28-2.50, P < 0.00001). 21 Furthermore, in palliative setting, sarcopenic patients with HCC treated with kinase inhibitors like sorafenib or lenvatinib showed lower OS (HR = 2.24, 95% CI: 1.60-3.14, P < 0.00001) than patients without sarcopenia. 21 Also, AT plays an important role in HCC.…”

Section: Discussionmentioning

confidence: 92%

Prognostic role of radiomics‐based body composition analysis for the 1‐year survival for hepatocellular carcinoma patients

Saalfeld,

Kreher,

Hille

et al. 2023

J cachexia sarcopenia muscle

Self Cite

View full text Add to dashboard Cite

BackgroundParameters of body composition have prognostic potential in patients with oncologic diseases. The aim of the present study was to analyse the prognostic potential of radiomics‐based parameters of the skeletal musculature and adipose tissues in patients with advanced hepatocellular carcinoma (HCC).MethodsRadiomics features were extracted from a cohort of 297 HCC patients as post hoc sub‐study of the SORAMIC randomized controlled trial. Patients were treated with selective internal radiation therapy (SIRT) in combination with sorafenib or with sorafenib alone yielding two groups: (1) sorafenib monotherapy (n = 147) and (2) sorafenib and SIRT (n = 150). The main outcome was 1‐year survival. Segmentation of muscle tissue and adipose tissue was used to retrieve 881 features. Correlation analysis and feature cleansing yielded 292 features for each patient group and each tissue type. We combined 9 feature selection methods with 10 feature set compositions to build 90 feature sets. We used 11 classifiers to build 990 models. We subdivided the patient groups into a train and validation cohort and a test cohort, that is, one third of the patient groups.ResultsWe used the train and validation set to identify the best feature selection and classification model and applied it to the test set for each patient group. Classification yields for patients who underwent sorafenib monotherapy an accuracy of 75.51% and area under the curve (AUC) of 0.7576 (95% confidence interval [CI]: 0.6376–0.8776). For patients who underwent treatment with SIRT and sorafenib, results are accuracy = 78.00% and AUC = 0.8032 (95% CI: 0.6930–0.9134).ConclusionsParameters of radiomics‐based analysis of the skeletal musculature and adipose tissue predict 1‐year survival in patients with advanced HCC. The prognostic value of radiomics‐based parameters was higher in patients who were treated with SIRT and sorafenib.

show abstract

Prevalence and role of low skeletal muscle mass (LSMM) in hepatocellular carcinoma. A systematic review and meta-analysis

Cited by 21 publications

References 47 publications

Influence of diabetes mellitus and effectiveness of metformin on hepatocellular carcinoma

Influence of diabetes mellitus and effectiveness of metformin on hepatocellular carcinoma

Prevalence of Sarcopenia in Patients With COVID-19: A Systematic Review and Meta-Analysis

Prognostic role of radiomics‐based body composition analysis for the 1‐year survival for hepatocellular carcinoma patients

Contact Info

Product

Resources

About